CL2016001424A1 - Composiciones de liberación retardada de lionaclotida - Google Patents
Composiciones de liberación retardada de lionaclotidaInfo
- Publication number
- CL2016001424A1 CL2016001424A1 CL2016001424A CL2016001424A CL2016001424A1 CL 2016001424 A1 CL2016001424 A1 CL 2016001424A1 CL 2016001424 A CL2016001424 A CL 2016001424A CL 2016001424 A CL2016001424 A CL 2016001424A CL 2016001424 A1 CL2016001424 A1 CL 2016001424A1
- Authority
- CL
- Chile
- Prior art keywords
- lysoclotide
- delayed release
- release compositions
- delayed
- liberation
- Prior art date
Links
- 230000003111 delayed effect Effects 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000010643 digestive system disease Diseases 0.000 abstract 1
- 208000018685 gastrointestinal system disease Diseases 0.000 abstract 1
- KXGCNMMJRFDFNR-WDRJZQOASA-N linaclotide Chemical compound C([C@H](NC(=O)[C@@H]1CSSC[C@H]2C(=O)N[C@H]3CSSC[C@H](N)C(=O)N[C@H](C(N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N2)=O)CSSC[C@H](NC(=O)[C@H](C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC(N)=O)NC3=O)C(=O)N[C@H](C(NCC(=O)N1)=O)[C@H](O)C)C(O)=O)C1=CC=C(O)C=C1 KXGCNMMJRFDFNR-WDRJZQOASA-N 0.000 abstract 1
- 229960000812 linaclotide Drugs 0.000 abstract 1
- 108010024409 linaclotide Proteins 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
- A61K9/4825—Proteins, e.g. gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nutrition Science (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361914952P | 2013-12-11 | 2013-12-11 | |
| US201361914951P | 2013-12-11 | 2013-12-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001424A1 true CL2016001424A1 (es) | 2017-09-08 |
Family
ID=52293217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001424A CL2016001424A1 (es) | 2013-12-11 | 2016-06-10 | Composiciones de liberación retardada de lionaclotida |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US20160310560A1 (enExample) |
| EP (2) | EP3821881A1 (enExample) |
| JP (4) | JP6964380B2 (enExample) |
| KR (3) | KR102337809B1 (enExample) |
| CN (3) | CN115089556A (enExample) |
| AU (3) | AU2014362220B2 (enExample) |
| CA (1) | CA2933587C (enExample) |
| CL (1) | CL2016001424A1 (enExample) |
| CY (1) | CY1123953T1 (enExample) |
| DK (1) | DK3079669T3 (enExample) |
| EA (1) | EA201691216A1 (enExample) |
| EC (2) | ECSP16059106A (enExample) |
| ES (1) | ES2838007T3 (enExample) |
| HR (1) | HRP20201753T1 (enExample) |
| HU (1) | HUE052981T2 (enExample) |
| IL (2) | IL246155A0 (enExample) |
| LT (1) | LT3079669T (enExample) |
| MX (2) | MX386584B (enExample) |
| NZ (2) | NZ759512A (enExample) |
| PE (2) | PE20211976A1 (enExample) |
| PH (1) | PH12016501122B1 (enExample) |
| PL (1) | PL3079669T3 (enExample) |
| PT (1) | PT3079669T (enExample) |
| RS (1) | RS61133B1 (enExample) |
| SG (2) | SG10201804817TA (enExample) |
| SI (1) | SI3079669T1 (enExample) |
| SM (1) | SMT202000686T1 (enExample) |
| UA (1) | UA119335C2 (enExample) |
| WO (2) | WO2015089326A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| CA2936748C (en) | 2014-10-31 | 2017-08-08 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
| WO2016125064A1 (en) * | 2015-02-02 | 2016-08-11 | Aurobindo Pharma Ltd | Stable compositions comprising linaclotide |
| WO2016197042A1 (en) * | 2015-06-05 | 2016-12-08 | Ironwood Pharmaceuticals, Inc. | Modified or targeted release formulations of linaclotide |
| US10588864B2 (en) | 2016-03-11 | 2020-03-17 | Gateway Pharmaceuticals LLC | Pharmaceutical compositions for colon-specific delivery |
| WO2017156214A1 (en) * | 2016-03-11 | 2017-09-14 | Gateway Pharmaceutical LLC | Pharmaceutical compositions for colon-specific delivery |
| WO2018065826A1 (en) * | 2016-10-06 | 2018-04-12 | Sucampo Ag | Multilayer beads for pharmaceutical use |
| MA47112A (fr) * | 2016-12-21 | 2019-10-30 | Ironwood Pharmaceuticals Inc | Procédés de traitement du syndrome du côlon irritable avec des formulations à libération modifiée ou retardée de linaclotide |
| KR102227486B1 (ko) * | 2017-06-30 | 2021-03-12 | 롯데정밀화학 주식회사 | 프로톤 펌프 저해제를 포함하는 경구용 고형제제 조성물, 이를 포함하는 경구용 고형제제 및 그 제조방법 |
| BR112020019128A2 (pt) * | 2018-03-23 | 2021-01-12 | Palatin Technologies, Inc. | Formulação farmacêutica de liberação em trato gastrointestinal inferior; formulação farmacêutica de liberação no trato gastrointestinal inferior preparada por um processo; processo; formulação de liberação modificada; composição farmacêutica adequada para administração oral para tratamento de uma doença inflamatória intestinal; e método de tratamento de doença inflamatória intestinal (ibd) em um paciente humano com ibd |
| US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
| CN114206324A (zh) * | 2019-06-10 | 2022-03-18 | 硬木药品公司 | 治疗与腹泻占主导的肠易激综合征相关的腹部疼痛 |
| KR102104507B1 (ko) * | 2019-08-23 | 2020-04-24 | 브릿지바이오테라퓨틱스(주) | 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법 |
| CN110935007B (zh) * | 2019-12-12 | 2023-06-23 | 烟台大学 | 利那洛肽复方组合物、制剂及其用途和制备方法 |
| GB202017863D0 (en) * | 2020-11-12 | 2020-12-30 | Intract Pharma Ltd | Novel compositions |
| EP4340838A4 (en) * | 2021-05-19 | 2025-04-16 | Alberto Paz | ORALLY ADMINISTERED COMPOSITIONS FOR CANCER TREATMENT |
| WO2024076577A1 (en) * | 2022-10-03 | 2024-04-11 | Brim Biotechnology, Inc. | Compositions comprising pedf-derived short peptides (pdsp) and uses thereof |
| JPWO2024143501A1 (enExample) * | 2022-12-28 | 2024-07-04 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7304036B2 (en) | 2003-01-28 | 2007-12-04 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| US7371727B2 (en) | 2003-01-28 | 2008-05-13 | Microbia, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CN201252259Y (zh) * | 2008-07-24 | 2009-06-03 | 富士康(昆山)电脑接插件有限公司 | 电连接器 |
| NZ591713A (en) * | 2008-08-15 | 2013-07-26 | Ironwood Pharmaceuticals Inc | Solid stable formulations of linaclotide for oral administration |
| US20100221329A1 (en) * | 2008-12-03 | 2010-09-02 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
| US20130012454A1 (en) * | 2009-07-06 | 2013-01-10 | Ironwood Pharmaceuticals, Inc. | Orally Disintegrating Compositions of Linaclotide |
| JP2013501071A (ja) * | 2009-08-06 | 2013-01-10 | アイロンウッド ファーマシューティカルズ， インコーポレイテッド | リナクロチドを含む処方物 |
| MX2012001691A (es) * | 2009-08-12 | 2012-02-29 | Forest Lab Holdings Ltd | Composiciones de linaclotida que se desintegran oralmente. |
| WO2011020054A1 (en) * | 2009-08-13 | 2011-02-17 | Ironwood Pharmaceuticals Inc. | Method for modulating the pharmacodynamic effect of orally administered guanylate cyclase receptor agonists |
| PL2536742T3 (pl) * | 2010-02-17 | 2017-11-30 | Ironwood Pharmaceuticals, Inc. | Leczenie zaburzeń żołądkowo-jelitowych |
| EP3626253B8 (en) * | 2010-08-11 | 2022-04-20 | Ironwood Pharmaceuticals, Inc. | Stable formulations of linaclotide |
| WO2012034068A1 (en) * | 2010-09-11 | 2012-03-15 | Ironwood Pharmaceuticals, Inc. | Treatment of constipation-predominant irritable bowel syndrome |
| JP2012155108A (ja) * | 2011-01-26 | 2012-08-16 | Kyocera Document Solutions Inc | 現像ローラ、現像装置および画像形成装置 |
| DK2776055T3 (en) * | 2011-08-17 | 2017-03-06 | Ironwood Pharmaceuticals Inc | TREATMENTS FOR GASTROINTESTINAL DISORDERS |
| BR112014007753B1 (pt) * | 2011-09-30 | 2021-07-06 | Astellas Pharma Inc. | composição farmacêutica granular, formulação e método para produção |
| US20140018307A1 (en) * | 2012-07-12 | 2014-01-16 | Forest Laboratories Holdings Ltd. | Linaclotide compositions |
| EP3718557A3 (en) * | 2013-02-25 | 2020-10-21 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonist sp-333 for use in colonic cleansing |
| UA119335C2 (uk) * | 2013-12-11 | 2019-06-10 | Айронвуд Фармасьютикалз, Інк. | Композиції лінаклотиду з затриманим вивільненням |
-
2014
- 2014-11-12 UA UAA201607434A patent/UA119335C2/uk unknown
- 2014-12-11 MX MX2016007625A patent/MX386584B/es unknown
- 2014-12-11 CN CN202210517834.4A patent/CN115089556A/zh active Pending
- 2014-12-11 SG SG10201804817TA patent/SG10201804817TA/en unknown
- 2014-12-11 CA CA2933587A patent/CA2933587C/en active Active
- 2014-12-11 US US15/103,634 patent/US20160310560A1/en not_active Abandoned
- 2014-12-11 KR KR1020167018606A patent/KR102337809B1/ko active Active
- 2014-12-11 LT LTEP14824655.6T patent/LT3079669T/lt unknown
- 2014-12-11 HU HUE14824655A patent/HUE052981T2/hu unknown
- 2014-12-11 SM SM20200686T patent/SMT202000686T1/it unknown
- 2014-12-11 RS RS20201435A patent/RS61133B1/sr unknown
- 2014-12-11 NZ NZ759512A patent/NZ759512A/en unknown
- 2014-12-11 NZ NZ721952A patent/NZ721952A/en unknown
- 2014-12-11 JP JP2016538745A patent/JP6964380B2/ja active Active
- 2014-12-11 CN CN201480075352.1A patent/CN106659687A/zh active Pending
- 2014-12-11 PT PT148246556T patent/PT3079669T/pt unknown
- 2014-12-11 DK DK14824655.6T patent/DK3079669T3/da active
- 2014-12-11 EP EP20198666.8A patent/EP3821881A1/en active Pending
- 2014-12-11 SG SG11201604729QA patent/SG11201604729QA/en unknown
- 2014-12-11 ES ES14824655T patent/ES2838007T3/es active Active
- 2014-12-11 AU AU2014362220A patent/AU2014362220B2/en active Active
- 2014-12-11 WO PCT/US2014/069838 patent/WO2015089326A1/en not_active Ceased
- 2014-12-11 PE PE2021000748A patent/PE20211976A1/es unknown
- 2014-12-11 HR HRP20201753TT patent/HRP20201753T1/hr unknown
- 2014-12-11 KR KR1020237008167A patent/KR20230039764A/ko not_active Ceased
- 2014-12-11 EA EA201691216A patent/EA201691216A1/ru unknown
- 2014-12-11 WO PCT/US2014/069851 patent/WO2015089335A1/en not_active Ceased
- 2014-12-11 PH PH1/2016/501122A patent/PH12016501122B1/en unknown
- 2014-12-11 PL PL14824655T patent/PL3079669T3/pl unknown
- 2014-12-11 KR KR1020217039962A patent/KR102509291B1/ko active Active
- 2014-12-11 CN CN202011156517.1A patent/CN112569199A/zh active Pending
- 2014-12-11 EP EP14824655.6A patent/EP3079669B1/en active Active
- 2014-12-11 US US15/103,616 patent/US20160310559A1/en not_active Abandoned
- 2014-12-11 SI SI201431715T patent/SI3079669T1/sl unknown
- 2014-12-11 PE PE2016000804A patent/PE20161373A1/es unknown
-
2016
- 2016-06-09 IL IL246155A patent/IL246155A0/en unknown
- 2016-06-10 MX MX2021011906A patent/MX2021011906A/es unknown
- 2016-06-10 CL CL2016001424A patent/CL2016001424A1/es unknown
- 2016-07-08 EC ECIEPI201659106A patent/ECSP16059106A/es unknown
-
2017
- 2017-02-17 US US15/435,701 patent/US20170157200A1/en not_active Abandoned
- 2017-09-28 US US15/718,075 patent/US20180015139A1/en not_active Abandoned
-
2019
- 2019-02-21 JP JP2019029432A patent/JP2019073559A/ja active Pending
- 2019-09-11 US US16/567,082 patent/US20200038476A1/en not_active Abandoned
-
2020
- 2020-04-01 AU AU2020202319A patent/AU2020202319B2/en active Active
- 2020-11-26 CY CY20201101128T patent/CY1123953T1/el unknown
-
2021
- 2021-05-06 IL IL283012A patent/IL283012A/en unknown
- 2021-05-06 JP JP2021078445A patent/JP7483656B2/ja active Active
- 2021-09-28 EC ECSENADI202172161A patent/ECSP21072161A/es unknown
- 2021-10-18 US US17/503,601 patent/US20220031802A1/en not_active Abandoned
-
2022
- 2022-03-18 AU AU2022201891A patent/AU2022201891A1/en not_active Abandoned
-
2023
- 2023-07-14 JP JP2023115832A patent/JP2023126475A/ja active Pending
- 2023-11-09 US US18/505,414 patent/US20240075094A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001424A1 (es) | Composiciones de liberación retardada de lionaclotida | |
| IL264065A (en) | Oral gastroretentive formulations and uses thes thereof | |
| MX2015009105A (es) | Composiciones en solucion solida y su uso en inflamacion cronica. | |
| EP3166648A4 (en) | Compositions and delivery methods for treating dental infections, inflammation, sensitivity, and for use in dental restorations | |
| IL285440A (en) | Oral compositions containing octreotide in combination with other therapeutic agents for tretment of acromegaly | |
| IL245429A0 (en) | A pharmaceutical preparation containing a derivative of glutarimide and its use in the treatment of eosinophilic diseases | |
| ME03483B (me) | Amorfni letermovir i njegove čvrste farmaceutske formulacije za oralno davanje | |
| CL2017001483A1 (es) | Formulación de relación fija de insulina glargina/lixisenatida | |
| MX2015009045A (es) | Composiciones y metodos para tratar el dolor severo. | |
| PL3003285T3 (pl) | Stała farmaceutyczna postać dawkowania do uwalniania co najmniej dwóch substancji czynnych w jamie ustnej | |
| SMT202500321T1 (it) | Composizioni liofilizzate ad area superficiale elevata comprendenti arsenico per la somministrazione orale a pazienti | |
| IL240666A0 (en) | Pharmaceutical preparations for oral administration and their uses | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| HUE061697T2 (hu) | Stabil gyógyszerkészítmény orális adagolásra | |
| SG11201911930SA (en) | Methods and compositions for substance use disorder vaccine formulations and uses thereof | |
| CR20160353A (es) | Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| KR101809800B9 (ko) | 전복 내장 유래의 항알러지 효과를 가지는 펩타이드가 함유된 약학 조성물 | |
| ZA201604100B (en) | Gastro-retentive oral pharmaceutical compositions | |
| GB201410869D0 (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| PE20151432A1 (es) | Formulaciones de lorazepam de liberacion sostenida | |
| FR3007654B1 (fr) | Composition de solute de rehydratation orale contenant des probiotiques | |
| PL3377044T3 (pl) | Kompozycje ibuprofenu do bezpośredniego podawania doustnego | |
| PL3072529T3 (pl) | Kompozycja zawierająca wemurafenib i HPMC-AS | |
| PT3177283T (pt) | Composto ativo e composição relacionada pata utilização dermatológica no campo farmacêutico ou cosmético | |
| CL2013000835A1 (es) | Compuestos derivados de metilciclohexano, moduladores del oxido nitrico; composicion farmaceutica que los comprende y su uso en el tratamiento y/o profilaxis del dolor cronico o agudo. |